Aktienanalyse zu Fennec Pharmaceuticals Inc (FENC)FENCFennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Fennec Pharmaceuticals Inc is a good buy right now due to its current price of $10.08, which is significantly below the analyst price targets of $16 and $18. The company has shown strong revenue growth, with Q1 2026 revenues of $15.11 million, a 72.7% year-over-year increase, and a gross margin of 96.23% in Q1 2026. The main risk is its current RSI of 38.81, indicating potential oversold conditions, but the positive earnings surprise of 400% in the last quarter suggests strong momentum.

1 analysts cover FENC: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 14.67.